Krystal Biotech has paused enrollment of its trial testing the intratumoral form of its experimental cancer drug KB707, citing a shift in development.
The decision comes ahead of a scheduled end-of-phase-2 meeting with the FDA in October, during which the company plans to discuss a potential approval path for the inhaled version of KB707 to treat nonsmall cell lung cancer, according to an Aug. 21 news release from the drugmaker.
Krystal Biotech said it is now focusing on the inhaled formulation, citing early signs of efficacy, including a 36% response rate in heavily pretreated nonsmall cell lung cancer patients.
While the trial is no longer enrolling new patients, those already in the study will continue to be monitored, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
